|
|
Article: Morning Alert for Cypress Bioscience Inc.
- Article from:
- M2 Presswire
- Article date:
- May 23, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-23 May 2007-Biotech News: Morning Alert for Cypress Bioscience Inc(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:23052007
Morning Alert for Cypress Bioscience Inc (NASDAQ:CYPB)
Cypress Bioscience, Inc. provides products for the treatment of functional somatic syndromes and other central nervous system disorders in the United States. The company is developing milnacipran, a norepinephrine serotonin reuptake inhibitor that is in second Phase III trial for the treatment of fibromyalgia syndrome. It has collaboration/license agreements with Collegium Pharmaceutical, Inc., Forest Laboratories, Inc., Pierre Fabre, and Organon. Cypress ...